Pre-surgery treatment for stage III–IV melanoma with two medicines
Part of Cancer clinical trials.
This trial tests two medicines given before surgery to shrink stage III–IV acral melanoma (a melanoma type on the hands/feet) and improve outcomes. If the tumors respond, surgery can happen afterward as planned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 18 to 75, and you have resectable stage III–IV acral melanoma (melanoma that can be surgically removed) with at least one measurable tumor spot
- You have not taken any anti-cancer medicines yet for this melanoma (no prior anti–PD-1/PD-L1 or VEGF-targeted pills/therapy)
- You can provide tumor tissue from a biopsy (before surgery) or tissue removed during surgery for genetic testing
- You must have an “activity” score (ECOG) of 0 or 1 and be expected to live at least 12 weeks
- Blood, liver, kidney, and heart tests must be within required limits, and you must be able to swallow pills normally
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
This trial tests a combination of two drugs, toripalimab (an immunotherapy) and endostatin (which targets blood vessels), given before and after surgery for stage II melanoma. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of three medicines (pucotenlimab, lenvatinib, and temozolomide) given before surgery to shrink stage IIB or III acral melanoma. The goal is to see if this treatment can improve outcomes for people whose melanoma can be removed by surgery.
This study tests a new oral drug called ST-1898 for people with advanced acral melanoma that has not responded to standard treatments. It aims to see if the drug can shrink or slow the growth of the cancer.
This trial tests a combination of three immunotherapy drugs (cemiplimab, fianlimab, and ipilimumab) before surgery in people with melanoma that can be surgically removed. The goal is to see if this treatment helps shrink the cancer and improves outcomes.
Hear when a new Acral Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.